News | Cardio-oncology | June 15, 2017

New Echo Protocol Aids Monitoring Children’s Heart Abnormalities Due to Chemotherapy

Pediatric echo protocols for cardio-oncology cardiotoxicity exams.

 June 15, 2017 – Children who have suffered from cancer may also have lasting side effects from the drugs used in the treatment of cancer, or chemotherapy-induced cardiotoxicity. The use of anthracyclines, very effective chemotherapy drugs, can be limited by development of cardiotoxicity, which has been traditionally monitored by echocardiography. A recent study at Children’s Hospital of Michigan used real-time 3-D imaging to detect early functional abnormalities associated with cardiotoxicity in the hearts of children following anthracycline chemotherapy.

“In our research study, we evaluated heart function of children who had completed anthracycline chemotherapy for cancer using a real-time 3-D echocardiography technique,” said lead author Sanjeev Aggarwal, M.D., pediatric cardiologist at The Children's Hospital of Michigan and Wayne State University School of Medicine, Detroit, Mich. “We found that, an average of five years after chemotherapy, asymptomatic children who had normal volume of the ventricles of the heart and normal ejection fraction, still had significant left ventricular dyssynchrony on the 3D echo. Dyssynchrony is a difference in contraction timing of various heart segments. The ability of this noninvasive bedside technique to diagnose cardiac dysfunction in the subclinical stage, even before abnormalities can be detected on a conventional echo, may open the possibilities of timely intervention and prevention of progression of the cardiotoxicity. Currently, when cardiotoxicity is detected, it can be irreversible. Further longitudinal studies are needed.” 
 
Researchers on the study, Left Ventricular Dyssynchrony and Real Time 3-D Echocardiogram in Children Following Chemotherapy include Sanjeev Aggarwal, M.D., and Gilda Kadiu, RDCS from Children's Hospital of Michigan.
 
Aggarwal presented a poster based on this research during the recent ASE 28th Annual Scientific Sessions. 

Watch the VIDEO "Assessing Cardiotoxicity Response With Cardio-Oncology Echo Imaging."  This is an interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University, at the American Society of Echocardiography (ASE) 2016 annual meeting. Asch discusses the technology used for cardio-oncology cardiotoxcity assessments and how to set up these types of collaborative programs between oncology and cardiology. For more information, read the article Assessing Cardiotoxicity Due to Cancer Therapy.

Read the related article “Assessing Cardiotoxicity Due to Cancer Therapy.” 

For more information: ASEcho.org
 

Related Content

New echo technology and products at the 2018 ASE meeting.
Feature | ASE | June 22, 2018
More than 60 companies and organizations are displaying their latest products and services at the 2018 American Socie
GE Healthcare Vivid T8 cardiac ultrasound, highlights from the American Society of Echo ASE 2017
Feature | ASE | June 26, 2017
June 26, 2017 — Here is a list of some key clinical presentations and video interviews with cardiac ultrasound though
Videos | ASE | June 30, 2016
DAIC/ITN editor Dave Fornell shares some of the innovative new technologies on the show floor of the American Society
Overlay Init